MIMickey Ising

Mickey Ising

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mickey Ising has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Mark S. Slaughter

    Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, Kentucky

    9 shared publications
  • Michael A. Sobieski

    From the *School of Medicine, †Department of Cardiovascular and Thoracic Surgery, and ‡Department of Bioengineering, University of Louisville, Louisville, Kentucky

    8 shared publications
  • Guruprasad A. Giridharan

    From the *Department of Bioengineering, University of Louisville, Louisville, Kentucky; †School of Medicine, University of Louisville, Louisville, Kentucky; ‡Department of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky; §College of Mechanical Engineering, Purdue University, West Lafayette, Indiana; and ¶Section of Cardiothoracic Surgery, Indiana University School of Medicine, James Whitcomb Riley Hospital for Children, Indianapolis, Indiana

    5 shared publications
  • Steven C. Koenig

    From the *School of Medicine, †Department of Cardiovascular and Thoracic Surgery, and ‡Department of Bioengineering, University of Louisville, Louisville, Kentucky

    5 shared publications
  • Jaimin R. Trivedi

    Department of Cardiovascular and Thoracic Surgery, University of Louisville School of Medicine, Louisville, KY, USA

    3 shared publications
  • Mark S. Slaughter

    Department of Cardiovascular and Thoracic Surgery, University of Louisville School of Medicine, Louisville, KY, USA

    3 shared publications

Latest Publications

  • Open Access

    Commentary: Supporting a left ventricular assist device to transplant, the right way

    by Mickey S. Ising, J. Hunter Mehaffey

  • Influence of Neoadjuvant Radiation Dose on Patients Undergoing Esophagectomy and Survival in Locally Advanced Esophageal Cancer

    by Mickey S. Ising, Katy Marino, Jaimin R. Trivedi, Adam A. Rojan, Neal E. Dunlap, Victor van Berkel, Matthew P. Fox


  • Use of drug intoxicated donors for lung transplant: Impact on survival outcomes

    by William M. Whited, Mickey S. Ising, Jaimin R. Trivedi, Matthew P. Fox, Victor van Berkel

    Introduction: The number of increasing deaths due to the opioid epidemic has led to a potential greater supply of organ donors. There is hesitancy to use drug intoxicated donors, and we evaluated their impact on post‐transplant survival.Background: Patients ≥18 years of age undergoing lung transplantation and donors from whom at least one organ was donated between January 2005 and March 2015 were selected from the United Network of Organ Sharing database. Baseline characteristics and post‐transplant survival were compared between drug intoxicated and all other donors.Results: The utilization of drug intoxicated donors increased from 1.86% in 2005 to 6.23% in 2014. The 2 study groups had similar characteristics including age, gender, and Lung Allocation Score. As compared to all other donors, drug intoxicated donors were younger (29.1 ± 9.4 vs 34.6 ± 13.4 years, P < .0001), less likely to be male (52% vs 61%, P < .0001), and had a greater smoking history (14% vs 11%, P .04). There was no difference in post–lung transplant survival at 1, 3, and 5 years between drug intoxicated donors (85%, 64%, and 47%) and non‐drug intoxicated donors (83%, 65%, and 51%).Conclusion: Transplantation utilizing drug intoxicated donor lungs has significantly increased over the past decade without significantly impacting post‐transplant survival.


  • Open Access

    Changing demographics of heart donors: The impact of donor drug intoxication on posttransplant survival

    by Mickey S. Ising, Michele Gallo, William M Whited, Mark S. Slaughter, Jaimin R. Trivedi


  • Heart Transplant Survival Based on Recipient and Donor Risk Scoring: A UNOS Database Analysis

    by Jaimin R. Trivedi, Allen Cheng, Mickey Ising, Andrew Lenneman, Emma Birks, Mark S. Slaughter

    Unlike the lung allocation score, currently, there is no quantitative scoring system available for patients on heart transplant waiting list. By using United Network for Organ Sharing (UNOS) data, we aim to generate a scoring system based on the recipient and donor risk factors to predict posttransplant survival. Available UNOS data were queried between 2005 and 2013 for heart transplant recipients aged ≥18 years to create separate cox-proportional hazard models for recipient and donor risk scoring. On the basis of risk scores, recipients were divided into five groups and donors into three groups. Kaplan–Meier curves were used for survival. Total 17,131 patients had heart transplant within specified time period. Major factors within high-risk groups were body mass index > 30 kg/m2 (46%), mean pulmonary artery pressure >30 mmHg (65%), creatinine > 1.5 mg% (63%), bilirubin > 1.5 mg% (54%), noncontinuous-flow left ventricular assist devices (45%) for recipients and gender mismatch (81%) and ischemia time >4 hours (88%) for donors. Survival in recipient groups 1, 2, 3, 4, and 5 at 5 years was 81, 80, 77, 74, and 62%, respectively, and in donor groups 1, 2, and 3 at 5 years was 79, 77, and 70%, respectively (p < 0.001). Combining donor and recipient groups based on scoring showed acceptable survival in low-risk recipients with high-risk donor (75% at 5 years). A higher recipient and donor risk score are associated with worse long-term survival. A low-risk recipient transplanted with high-risk donor has acceptable survival at 5 years, but high-risk recipient combined with a high-risk donor has marginal results. Using an objective scoring system could help get the best results when utilizing high-risk donors.


  • The current state of left ventricular assist devices: challenges facing further development

    by Erin M Schumer, Mickey S Ising, Mark S Slaughter

    Heart failure is a clinical syndrome with significant morbidity and mortality. The use of left ventricular assist devices has improved outcomes for patients with advanced heart failure in the face of limited donor organs available for heart transplantation. This article describes current issues and limitations facing the left ventricular assist device field and explores how the field can be expanded in this setting.


  • Feasibility of Pump Speed Modulation for Restoring Vascular Pulsatility with Rotary Blood Pumps

    by Mickey S. Ising, Michael A. Sobieski, Mark S. Slaughter, Steven C. Koenig, Guruprasad A. Giridharan

    Continuous flow (CF) left ventricular assist devices (LVAD) diminish vascular pressure pulsatility, which may be associated with clinically reported adverse events including gastrointestinal bleeding, aortic valve insufficiency, and hemorrhagic stroke. Three candidate CF LVAD pump speed modulation algorithms designed to augment aortic pulsatility were evaluated in mock flow loop and ischemic heart failure (IHF) bovine models by quantifying hemodynamic performance as a function of mean pump speed, modulation amplitude, and timing. Asynchronous and synchronous copulsation (high revolutions per minute [RPM] during systole, low RPM during diastole) and counterpulsation (low RPM during systole, high RPM during diastole) algorithms were tested for defined modulation amplitudes (±300, ±500, ±800, and ±1,100 RPM) and frequencies (18.75, 37.5, and 60 cycles/minute) at low (2,900 RPM) and high (3,200 RPM) mean LVAD speeds. In the mock flow loop model, asynchronous, synchronous copulsation, and synchronous counterpulsation algorithms each increased pulse pressure (ΔP = 931%, 210%, and 98% and reduced left ventricular external work (LVEW = 20%, 22%, 16%). Similar improvements in vascular pulsatility (1,142%) and LVEW (40%) were observed in the IHF bovine model. Asynchronous modulation produces the largest vascular pulsatility with the advantage of not requiring sensor(s) for timing pump speed modulation, facilitating potential clinical implementation.


  • Cavopulmonary Assist for the Failing Fontan Circulation

    by Guruprasad A. Giridharan, Mickey Ising, Michael A. Sobieski, Steven C. Koenig, Jun Chen, Steven Frankel, Mark D. Rodefeld

    Mechanical circulatory support—either ventricular assist device (VAD, left-sided systemic support) or cavopulmonary assist device (CPAD, right-sided support)—has been suggested as treatment for Fontan failure. The selection of left- versus right-sided support for failing Fontan has not been previously defined. Computer simulation and mock circulation models of pediatric Fontan patients (15–25 kg) with diastolic, systolic, and combined systolic and diastolic dysfunction were developed. The global circulatory response to assisted Fontan flow using VAD (HeartWare HVAD, Miami Lakes, FL) support, CPAD (Viscous Impeller Pump, Indianapolis, IN) support, and combined VAD and CPAD support was evaluated. Cavopulmonary assist improves failing Fontan circulation during diastolic dysfunction but preserved systolic function. In the presence of systolic dysfunction and elevated ventricular end-diastolic pressure (VEDP), VAD support augments cardiac output and diminishes VEDP, while increased preload with cavopulmonary assist may worsen circulatory status. Fontan circulation can be stabilized to biventricular values with modest cavopulmonary assist during diastolic dysfunction. Systemic VAD support may be preferable to maintain systemic output during systolic dysfunction. Both systemic and cavopulmonary support may provide best outcome during combined systolic and diastolic dysfunction. These findings may be useful to guide clinical cavopulmonary assist strategies in failing Fontan circulations.


  • Flow Modulation Algorithms for Intra-Aortic Rotary Blood Pumps to Minimize Coronary Steal

    by Mickey S. Ising, Steven C. Koenig, Michael A. Sobieski, Mark S. Slaughter, Guruprasad A. Giridharan

    Intra-aortic rotary blood pumps (IARBPs) have been used for partial cardiac support during cardiogenic shock, myocardial infarction, percutaneous coronary intervention, and potentially viable for long-term circulatory support. Intra-aortic rotary blood pump support continuously removes volume from the aortic root, which lowers left ventricular preload, external work (LVEW), and improves end-organ perfusion. However, IARBP support diminishes aortic root pressure and coronary artery. It may also create “coronary steal,” which may produce a myocardial hypoxic state adversely affecting patient outcomes. Our objective was to develop IARBP flow modulation algorithms to eliminate coronary steal and improve the myocardial supply-demand ratio without compromising the clinical benefits of restored end-organ perfusion and reduced LVEW. The hemodynamic responses of the native ventricle, coronary, and systemic vasculature to timing and synchronization of IARBP flow modulation (cyclic variation of pump flow) were investigated using a clinical heart failure (HF) computer simulation model. A total of more than 150 combinations of varying pulse widths and time-shifts to modulate IARBP flow were tested at mean IARBP flow rates of 2, 3, and 4 L/min, and compared with HF baseline values (no IARBP support). Increasing IARBP support augmented cardiac output and diminished LVEW. Nonmodulated IARBP support significantly diminished mean diastolic coronary flow (−49%) and myocardial supply-demand ratio (−12%) compared with HF baseline. Intra-aortic rotary blood pump flow modulation increased mean diastolic coronary flow (+17%) and myocardial supply-demand ratio (+24%) compared with nonmodulated IARBP (constant flow). Modulation and synchronization of IARBP support augmented coronary artery perfusion and myocardial supply-demand ratio in simulated clinical HF while also restoring end-organ perfusion and reducing LVEW. Implementation of IARBP support with flow modulation may prevent myocardial hypoxia and improve patient outcomes. However, even with flow modulation, IARBP support provides a smaller improvement in myocardial supply demand ratio compared to ventricular assist devices and intra-aortic balloon pumps.